| 期 |
栏目 |
标题 |
文件 |
| 卷 15, 编号 2 (2013) |
Articles |
Prognostic value of p53 expression in patients with stage I breast cancer |
|
| 卷 15, 编号 3 (2013) |
Articles |
Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii |
|
| 卷 15, 编号 4 (2013) |
Articles |
Bone mineral density in patient with breast cancer |
|
| 卷 16, 编号 4 (2014) |
Articles |
Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials) |
|
| 卷 17, 编号 1 (2015) |
Articles |
Breast cancer immunology: theory and prospects (review) |
|
| 卷 17, 编号 1 (2015) |
Articles |
A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian |
|
| 卷 17, 编号 1 (2015) |
Articles |
Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience) |
|
| 卷 18, 编号 1 (2016) |
Articles |
Rare morphological forms of breast cancer: features of surgical approach |
(Rus)
|
| 卷 18, 编号 1 (2016) |
Articles |
Features of surgical treatment of patients with breast cancer receiving preoperative systemic therapy |
(Rus)
|
| 卷 19, 编号 4 (2017) |
Articles |
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0 |
(Rus)
|
| 卷 19, 编号 4 (2017) |
Articles |
Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case |
(Rus)
|
| 卷 20, 编号 3 (2018) |
Articles |
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer |
(Rus)
|
| 卷 20, 编号 4 (2018) |
Articles |
Quality control of immunohistochemical analyzes in Russia: yesterday, today, tomorrow |
(Rus)
|
| 卷 21, 编号 2 (2019) |
Articles |
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review) |
(Rus)
|
| 卷 21, 编号 3 (2019) |
Articles |
The predictive value of digital mammography, breast ultrasound and their combination in the diagnosis of early breast cancer |
(Rus)
|
| 卷 21, 编号 3 (2019) |
Articles |
The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer |
(Rus)
|
| 卷 22, 编号 1 (2020) |
CLINICAL ONCOLOGY |
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Best Practice |
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience |
(Rus)
(Eng)
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
(Rus)
(Eng)
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer |
(Rus)
|
| 卷 23, 编号 2 (2021) |
CLINICAL ONCOLOGY |
Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization |
(Rus)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III |
(Rus)
|
| 卷 25, 编号 1 (2023) |
CLINICAL ONCOLOGY |
Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review |
(Rus)
|
| 卷 25, 编号 1 (2023) |
CLINICAL ONCOLOGY |
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review |
(Rus)
|
| 卷 25, 编号 2 (2023) |
CLINICAL ONCOLOGY |
Hydroxyethyldimethyldihydropyrimidine as the drug of choice for the prevention of paraprosthetic seromas in breast reconstructive surgery: A retrospective study |
(Rus)
|
| 卷 25, 编号 4 (2023) |
CLINICAL ONCOLOGY |
The use of hydroxyethyldimethyldihydropyrimidine to improve regeneration processes in a postoperative wound after sectoral resection of the breast |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study |
(Rus)
|
